Xiaozheng Fuzheng Oral Liquid

The results of preclinical animal experiments indicate that this product has a certain protective effect on the first stage (ischemic electrocardiogram S-T segment) and second stage of acute myocardial ischemia induced by posterior pituitary hormone in rats; it reduces the area of myocardial ischemia and necrosis after coronary artery ligation in dogs, and reduces the elevated electrocardiogram S-T segment; it reduces the blood pressure, left ventricular pressure, canine arterial blood pressure, left ventricular intraventricular pressure, maximum rise rate, heart rate and myocardial oxygen consumption in normal dogs; it reduces the levels of serum total cholesterol, triglycerides and low-density lipoprotein cholesterol in fed rabbits; it increases the coronary blood flow in isolated rat hearts, and inhibits thrombosis in experimental rabbits.

Salvia miltiorrhiza, safflower, Ligusticum chuanxiong, red peony root, Corydalis yanhusuo, wolfberry, processed Polygonum multiflorum, Cyperus rotundus.

This product is yellow-brown to dark brown granules: aromatic, slightly bitter.

Oral administration: 5 grams each time, 3 times a day, 4 weeks as a course of treatment.

Some patients may experience upper abdominal discomfort, nausea, belching, loose stools and other digestive tract symptoms after taking the medicine.

Not yet clear.

Drug interactions may occur if used with other drugs. Please consult your pharmacist or doctor for details.

Seal tightly and store in a cool, dry place.

20ml per bottle

Tentative one year

ORxes Biopharmaceuticals (Shenyang) Co., Ltd.

• Founded in:

  2004-08-09

• Address:

  No. 176, Shenbei Road, Huishan Economic Development Zone, Shenbei New District, Shenyang

• Tax NO.:

  91210100764362386F

• Registered Funds:

  115 million yuan

• Email:

  Log in to view